Navigation Links
Glide Pharma Completes £14.0 Million ($21.4 Million) Fundraising for Scale Up of Drug and Device Manufacturing Processes and Product Development
Date:2/26/2013

OXFORD, England, February 26, 2013 /PRNewswire/ --

Glide Pharma, the pharmaceutical development and device company focused on the needle-free administration of solid dose formulations, today announced that it has completed a £14.0 million ($21.4 million) investment round.  The fundraising was led by funds managed by Invesco Perpetual and supported by existing investors.  To date, Glide Pharma has successfully completed five funding rounds raising approximately £24.9 million.

Glide Pharma will use the funds to scale up the manufacturing process for its proprietary Glide SDI® solid dose injector system, including both the drug product and device. This includes the validation of an aseptic pilot-scale production line for clinical testing, and scale up for the manufacture of Glide SDI® device components.  The funds will also progress the development of the company's in-house programmes, which include epinephrine and parathyroid hormone.

"I am delighted to welcome Invesco Perpetual to Glide Pharma as an important new investor in this transformational fundraising.  This substantial investment round clearly demonstrates the confidence our shareholders have in our innovative technology, and its potential to revolutionise the delivery of therapeutics and vaccines," said Mark Kirby , Glide Pharma's Chairman.  "This fundraising follows recognition of Glide's novel technology by the UK government-backed Biomedical Catalyst scheme, which awarded the company £2.3 million funding for the development of a novel formulation of teriparatide (parathyroid hormone) for the treatment of osteoporosis."

The UK Biomedical Catalyst, which was announced by Prime Minister David Cameron in December 2011, is managed jointly by the Medical Research Council and the Technology Strategy Board.

About the Glide SDI® solid dose injector

The Glide SDI® is an innovative needle-free delivery system. The reusable injector uses a spring mechanism to administer a tiny solid dosage below the patient's skin, where it dissolves and releases the pharmaceutical. Glide's solid dose formulations eliminate the risk of needle-stick injuries and avoid time-consuming reconstitution. They also have the potential to modify the release of medicines and to improve stability, removing the need for refrigeration. The one-click action, pen-sized device is extremely easy to use, with medicines supplied in pre-filled disposable cassettes, making it ideal for self administration. In clinical testing, volunteers strongly preferred the Glide SDI® to traditional needle and syringe.

About Glide Pharma

Glide Pharma is a pharmaceutical development and device company focused on the easy, safe and convenient administration of solid dose formulations of therapeutics and vaccines. The company has a range of in-house and partnered programmes based on its proprietary solid dose injector, the Glide SDI®. Glide Pharma has a strong management team with extensive experience of the pharmaceutical, biotechnology and medical device sectors. The company has successfully completed five investment rounds, and is supported by a consortium of institutional and private technology investors, including Invesco Perpetual, Oxford Technology Venture Capital Trusts, Oxford Capital Partners and Hygea VCT.

Contacts

Ian Smith
Chief Executive
Glide Pharma
Tel: +44-(0)8700-853-700

Rob Budge
RJB Communications
Tel: +44-(0)1865-760-969
Mobile: +44-(0)7710-741-241


'/>"/>
SOURCE Glide Pharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Verathon, maker of GlideScope video laryngoscopes, provides free educational DVD to promote best practices in pediatric airway management.
2. TriReme Medical, Inc. Receives FDA Approval for Glider™ PTCA Catheter
3. CPhI in Partnership With PMI India Announces Pharma Project Management Conference
4. UBM Launches PharmaEvolution.com, an Online Peer-to-Peer Network for Pharmaceutical Industry Professionals
5. Alexza Pharmaceuticals Corporate Presentation to Be Webcast at Three Upcoming Investor Conferences
6. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Monday, March 4
7. ShangPharma Corporation Announces Extraordinary General Meeting of Shareholders
8. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
9. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2012 Financial Results on Thursday, March 7, 2013
10. Royalty Pharma Announces Proposal To Acquire Elan
11. Reckitt Benckiser Pharmaceuticals Inc. Receives FDA Response to Citizens Petition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... ALLENTOWN , Pa. and KALAMAZOO, Mich. ... Allentown, Penn. , and OptiMed Specialty Pharmacy ... a business partnership to offer a strategic hub service ... PMD Healthcare,s highly sought-after personal spirometer, Spiro PD 2.0, ... A spirometer is a medical device used ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , ... supply chains, has published the first annual edition of its Global CSR ... than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed ... ... & Performance Index ...
(Date:9/9/2017)... ... ... – Monday, September 18 th .The Brain Tumor Foundation (BTF) begins a ... public.Where:  BTF,s Mobile MRI Unit – a 70 ... D.C.What:BTF brings its nationwide initiative, the Road to Early Detection Sponsor-A-City Campaign ...
Breaking Medicine Technology:
(Date:9/26/2017)... ... September 26, 2017 , ... Atmosera ... Release Management as a Service (RMaaS) to automate the deployment of ... include any companies, e-tailers, and web development agencies who want to improve time-to-revenue ...
(Date:9/26/2017)... ... September 26, 2017 , ... ... not only entirely new and different, it is scientifically proven as well: ABAlife™. ... company has received an exclusive license agreement with BioTherapeutics Inc. for patented technology ...
(Date:9/26/2017)... , ... September 26, 2017 , ... ... shore, the John R. Elliott HERO Campaign for Designated Drivers proudly announced the ... Club. , Thirty-one local bars and restaurants took on the challenge of competing ...
(Date:9/26/2017)... ... ... Data Integrity: , The Key to FDA and GMP Compliance, ** Presented ... http://www.fdanews.com/fdadataintegrity , Consider this situation. The FDA gives simple instructions ... trustworthy and reliable … a more detailed evaluation may be warranted.” , That's ...
(Date:9/26/2017)... , ... September 26, 2017 , ... ... surgeon and the Chair of the Leg, Ankle, and Foot Section of the ... the only fellowship trained orthopedic surgeon at Hackensack UMC performing total ankle replacements. ...
Breaking Medicine News(10 mins):